- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02054871
RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
Randomised Controlled Trial to Evaluate the Reno-protective Benefits of Remote Ischaemic Preconditioning in Patients Undergoing Infrainguinal Peripheral Angioplasty
Study Overview
Detailed Description
Ischaemic preconditioning is an endogenous mammalian mechanism whereby a brief period of ischaemia and reperfusion confers resistance to subsequent prolonged ischaemic insults. First observed in the canine heart, subsequent investigators noted that brief ischaemia in remote organs e.g. skeletal muscle, induced protection in key central organs e.g. the heart. This remote ischaemic preconditioning (RIPC) does not require direct interference with the target organs' blood supply. It can be induced using blood pressure cuffs to produce brief episodes of upper limb ischaemia and reperfusion and confers protection upon numerous organs simultaneously. RIPC reduces myocardial injury following aortic aneurysm repair, cardiac surgery and angioplasty. It also reduces adverse ischaemic events up to six months following percutaneous coronary intervention, implying some medium-term effect.
To date ischaemic conditioning has been applied primarily to the heart however animal studies have shown pre conditioning to offer renal protection.
Fikret et al in 2012 in the Renal Protection Trial demonstrated a protective benefit with RIPC from the development of CIN in high risk patients undergoing elective coronary angiography.Whittaker and Przyklenk in 2011 explored this concept retrospectively using data from patients who had undergone emergency angioplasty for ST elevation myocardial infarction. The original trial was a RCT which examined the protective effect of postconditioning on myocardial ischemia. The authors retrospectively examined if study patients treated with multiple coronary balloon inflations had better renal function than patients not exposed to this remote conditioning. They concluded that patients in the conditioning group received 25% more contrast volume than the control group and showed no decline in renal function as demonstrated by examination of glomular filtration rate at day 3 post procedure in comparison to the control group which saw a significant decline in renal function. The need for contrast-based procedures is rising, with increasing numbers of patients undergoing endovascular procedures, as is the incidence of postcontrast renal failure, which has a reported mortality of 34%. The potential use of RIPC therefore to reduce the risk of kidney damage needs further investigation in a prospective study and the PAD patient group who are routinely exposed to contrast administration in angiography are an ideal study group.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kamsila Pillay, MbCHB
- Email: kamsilakp@yahoo.co.uk
Study Locations
-
-
-
Limerick, Ireland
- Recruiting
- HSE Mid Western Regional Hospital
-
Contact:
- Kamsila Pillay
- Email: kamsilakp@yahoo.co.uk
-
Sub-Investigator:
- Kamsila Pillay
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elective intra-arterial, infrainguinal peripheral angiography/angioplasty
- Written informed consent
- Patients >18yrs of age
- Patients with CKD (Stage2/3) as evidenced by eGFR <90ml/min/1.73m2
Exclusion Criteria:
- Severe renal impairment eGFR <30ml/min
- Evidence of acute renal failure or patients on dialysis
- History of previous CIN
- Contraindication to intravenous volume replacement therapy
- Pregnancy
- Patients on glibenclamide or nicorandil (these medications may interfere with RIPC)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EGFR 30-60
Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. |
A standard, CE-approved tourniquet cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles.
Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
|
Experimental: EGFR 60-90
Experimental: RIPC Remote preconditioning.
EGFR calculated using MDRD equation.
Oral hydration pre-procedural as reno-protective measure.
Preconditioning will be performed in the same manner as several previous trials.
Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
|
A standard, CE-approved tourniquet cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles.
Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
|
No Intervention: EGRF 30-60
No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection. Patients randomised to this group will receive routine care. |
|
No Intervention: EGRF 60-90
No Intervention: Remote preconditioning control EGFR calculated using MDRD equation.
Oral hydration pre-procedural as reno-protective measure.
Patients randomised to this group will receive routine care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal impairment
Time Frame: 72 hours post procedural
|
Serial assessment of renal biomarkers in serum and urine in 72 hour period post procedure
|
72 hours post procedural
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-inflammatory effect of RIPC
Time Frame: 3-6 months post recruitment
|
Assessment of additional postulated benefits of anti-inflammatory effects with RIPC in terms of decreased restenosis rates and lower inflammatory markers
|
3-6 months post recruitment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stewart Walsh, MCh FRCS, University of Limerick
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MWRH09644
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
Clinical Trials on RIPC
-
Helsinki University Central HospitalAcademy of Finland; Finska Läkaresällskapet (funding); Helsinki University Hospital...Recruiting
-
Oladipupo Olafiranye, MD, MSNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingContrast-induced Acute Kidney InjuryUnited States
-
Liverpool John Moores UniversityCompletedCardiovascular Disease RiskUnited Kingdom
-
Westfälische Wilhelms-Universität MünsterRecruitingSepsis | Acute Kidney Injury | Critically IllGermany
-
Seoul National University HospitalCompletedIschemic Reperfusion Injury | Radiotherapy | Other Reconstructive SurgeryKorea, Republic of
-
Seoul National University HospitalCompletedRemote Ischemic PreconditioningKorea, Republic of
-
Fundación Centro Nacional de Investigaciones Cardiovasculares...European CommissionRecruitingLymphoma | Anthracycline-induced Cardiac ToxicityNetherlands, Spain, Denmark, Germany, France, Portugal
-
Shanghai Zhongshan HospitalCompletedCardiac SurgeryChina
-
Changi General HospitalUniversity College Hospital GalwayCompletedContrast Induced Nephropathy | Remote Ischaemic PreconditioningSingapore
-
VA Office of Research and DevelopmentRecruitingHeart Failure | Acute Kidney Injury | Percutaneous Coronary Intervention | Contrast Induced Nephropathy | Coronary AngiographyUnited States